Which has higher earnings and valuation, GRAL or OMER?

Omeros has lower revenue, but higher earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 42.30 -$408.35M -$9.75 N/A Omeros N/A N/A -$3.35M $1.28 14.36

Is GRAL or OMER more profitable?

Omeros has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -236.95% -15.88% -14.02% Omeros N/A -164.92% 69.41%

Does the media prefer GRAL or OMER?

In the previous week, GRAIL had 7 more articles in the media than Omeros. MarketBeat recorded 10 mentions for GRAIL and 3 mentions for Omeros. Omeros' average media sentiment score of 0.67 beat GRAIL's score of 0.60 indicating that Omeros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omeros 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, COGT or OMER?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.16 N/A Omeros N/A N/A -$3.35M $1.28 14.36

Is COGT or OMER more profitable?

Cogent Biosciences' return on equity of -84.47% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -84.47% -47.72% Omeros N/A -164.92% 69.41%

Does the media prefer COGT or OMER?

In the previous week, Omeros had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 3 mentions for Omeros and 2 mentions for Cogent Biosciences. Omeros' average media sentiment score of 0.67 beat Cogent Biosciences' score of 0.55 indicating that Omeros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omeros 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OMER or TVTX?

In the previous week, Omeros had 1 more articles in the media than Travere Therapeutics. MarketBeat recorded 3 mentions for Omeros and 2 mentions for Travere Therapeutics. Omeros' average media sentiment score of 0.67 beat Travere Therapeutics' score of 0.00 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, OMER or ORKA?

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros N/A N/A -$3.35M $1.28 14.36 Oruka Therapeutics N/A N/A -$105.43M -$2.03 N/A

Is OMER or ORKA more profitable?

Oruka Therapeutics' return on equity of -21.65% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% Oruka Therapeutics N/A -21.65% -20.88%

Does the media refer more to OMER or ORKA?

In the previous week, Omeros had 1 more articles in the media than Oruka Therapeutics. MarketBeat recorded 3 mentions for Omeros and 2 mentions for Oruka Therapeutics. Omeros' average media sentiment score of 0.67 beat Oruka Therapeutics' score of 0.00 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is OMER or CRSP more profitable?

Omeros has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% CRISPR Therapeutics -3,368.72% -24.39% -18.25%

Does the media refer more to OMER or CRSP?

In the previous week, CRISPR Therapeutics had 4 more articles in the media than Omeros. MarketBeat recorded 7 mentions for CRISPR Therapeutics and 3 mentions for Omeros. CRISPR Therapeutics' average media sentiment score of 0.75 beat Omeros' score of 0.67 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Omeros (OMER) Competitors

$18.61 +0.14 (+0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$18.52 -0.09 (-0.51%)

As of 07:32 PM Eastern

Compare

OMER vs. GRAL, COGT, TVTX, ORKA, and CRSP

Should you buy Omeros stock or one of its competitors? Omeros's main competitors and comparable companies include GRAIL (GRAL), Cogent Biosciences (COGT), Travere Therapeutics (TVTX), Oruka Therapeutics (ORKA), and CRISPR Therapeutics (CRSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Omeros compare to GRAIL?

GRAIL (NASDAQ:GRAL) and Omeros (NASDAQ:OMER) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

48.8% of Omeros shares are owned by institutional investors. 1.8% of GRAIL shares are owned by insiders. Comparatively, 10.5% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Omeros has lower revenue, but higher earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	42.30	-$408.35M	-$9.75	N/A
Omeros	N/A	N/A	-$3.35M	$1.28	14.36

GRAIL has a beta of 2.81, meaning that its share price is 181% more volatile than the broader market. Comparatively, Omeros has a beta of 2.57, meaning that its share price is 157% more volatile than the broader market.

Omeros has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Omeros	N/A	-164.92%	69.41%

In the previous week, GRAIL had 7 more articles in the media than Omeros. MarketBeat recorded 10 mentions for GRAIL and 3 mentions for Omeros. Omeros' average media sentiment score of 0.67 beat GRAIL's score of 0.60 indicating that Omeros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omeros	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GRAIL presently has a consensus target price of $93.60, indicating a potential downside of 32.84%. Omeros has a consensus target price of $34.00, indicating a potential upside of 85.02%. Given Omeros' stronger consensus rating and higher possible upside, analysts plainly believe Omeros is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Omeros	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Omeros beats GRAIL on 11 of the 16 factors compared between the two stocks.

How does Omeros compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Omeros (NASDAQ:OMER) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, Omeros had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 3 mentions for Omeros and 2 mentions for Cogent Biosciences. Omeros' average media sentiment score of 0.67 beat Cogent Biosciences' score of 0.55 indicating that Omeros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omeros	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences presently has a consensus target price of $51.56, suggesting a potential upside of 65.10%. Omeros has a consensus target price of $34.00, suggesting a potential upside of 85.02%. Given Omeros' higher possible upside, analysts plainly believe Omeros is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Omeros	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

Cogent Biosciences' return on equity of -84.47% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
Omeros	N/A	-164.92%	69.41%

48.8% of Omeros shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 10.5% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cogent Biosciences has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Omeros has a beta of 2.57, suggesting that its share price is 157% more volatile than the broader market.

Cogent Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
Omeros	N/A	N/A	-$3.35M	$1.28	14.36

Summary

Omeros beats Cogent Biosciences on 10 of the 13 factors compared between the two stocks.

How does Omeros compare to Travere Therapeutics?

Omeros (NASDAQ:OMER) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

In the previous week, Omeros had 1 more articles in the media than Travere Therapeutics. MarketBeat recorded 3 mentions for Omeros and 2 mentions for Travere Therapeutics. Omeros' average media sentiment score of 0.67 beat Travere Therapeutics' score of 0.00 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

48.8% of Omeros shares are held by institutional investors. 10.5% of Omeros shares are held by insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Omeros presently has a consensus price target of $34.00, indicating a potential upside of 85.02%. Travere Therapeutics has a consensus price target of $69.50, indicating a potential upside of 22.57%. Given Omeros' higher possible upside, research analysts clearly believe Omeros is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Omeros has higher earnings, but lower revenue than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$1.28	14.36
Travere Therapeutics	$490.73M	10.89	-$25.55M	-$0.46	N/A

Omeros has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Travere Therapeutics' return on equity of -55.15% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Omeros has a beta of 2.57, suggesting that its stock price is 157% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Summary

Omeros beats Travere Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Omeros compare to Oruka Therapeutics?

Omeros (NASDAQ:OMER) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Omeros currently has a consensus target price of $34.00, suggesting a potential upside of 85.02%. Oruka Therapeutics has a consensus target price of $128.91, suggesting a potential upside of 53.34%. Given Omeros' higher possible upside, analysts clearly believe Omeros is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

48.8% of Omeros shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 10.5% of Omeros shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Omeros had 1 more articles in the media than Oruka Therapeutics. MarketBeat recorded 3 mentions for Omeros and 2 mentions for Oruka Therapeutics. Omeros' average media sentiment score of 0.67 beat Oruka Therapeutics' score of 0.00 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oruka Therapeutics' return on equity of -21.65% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
Oruka Therapeutics	N/A	-21.65%	-20.88%

Omeros has a beta of 2.57, suggesting that its share price is 157% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.37, suggesting that its share price is 137% less volatile than the broader market.

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$1.28	14.36
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Summary

Omeros beats Oruka Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Omeros compare to CRISPR Therapeutics?

Omeros (NASDAQ:OMER) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Omeros has a beta of 2.57, suggesting that its share price is 157% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

In the previous week, CRISPR Therapeutics had 4 more articles in the media than Omeros. MarketBeat recorded 7 mentions for CRISPR Therapeutics and 3 mentions for Omeros. CRISPR Therapeutics' average media sentiment score of 0.75 beat Omeros' score of 0.67 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omeros has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

48.8% of Omeros shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 10.5% of Omeros shares are owned by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Omeros has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$1.28	14.36
CRISPR Therapeutics	$3.51M	1,499.77	-$581.60M	-$4.76	N/A

Omeros presently has a consensus target price of $34.00, suggesting a potential upside of 85.02%. CRISPR Therapeutics has a consensus target price of $67.94, suggesting a potential upside of 24.79%. Given Omeros' stronger consensus rating and higher probable upside, equities analysts plainly believe Omeros is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.67

Summary

Omeros beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Omeros News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMER vs. The Competition

Export

Metric	Omeros	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.34B	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.65%	2.54%	16.76%
P/E Ratio	14.54	7.65	214.49	21.54
Price / Sales	N/A	1,292.25	607.75	91.81
Price / Cash	9.87	122.60	77.60	51.75
Price / Book	-10.88	16.63	10.92	6.30
Net Income	-$3.35M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-7.32%	-3.05%	-2.11%	-1.67%
1 Month Performance	-1.33%	-10.75%	-6.34%	-3.94%
1 Year Performance	341.00%	21.11%	8.81%	2.77%

Omeros Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMER Omeros	3.9574 of 5 stars	$18.61 +0.8%	$34.00 +82.7%	+346.1%	$1.34B	N/A	14.54	175	News Coverage
GRAL GRAIL	1.0466 of 5 stars	$132.63 +4.5%	$85.60 -35.5%	+113.6%	$5.67B	$147.17M	N/A	910	Analyst Forecast
COGT Cogent Biosciences	2.3308 of 5 stars	$31.86 -1.4%	$51.56 +61.8%	+123.6%	$5.61B	N/A	N/A	258	News Coverage
TVTX Travere Therapeutics	1.6591 of 5 stars	$61.57 +3.6%	$69.50 +12.9%	+129.3%	$5.60B	$490.73M	N/A	497
ORKA Oruka Therapeutics	2.2611 of 5 stars	$84.19 -0.3%	$128.91 +53.1%	+348.0%	$5.59B	N/A	N/A	68

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMER) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omeros (OMER) Competitors

OMER vs. GRAL, COGT, TVTX, ORKA, and CRSP

How does Omeros compare to GRAIL?

Summary

How does Omeros compare to Cogent Biosciences?

Summary

How does Omeros compare to Travere Therapeutics?

Summary

How does Omeros compare to Oruka Therapeutics?

Summary

How does Omeros compare to CRISPR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omeros (OMER) Competitors

OMER vs. GRAL, COGT, TVTX, ORKA, and CRSP

How does Omeros compare to GRAIL?

Do insiders & institutionals have more ownership in GRAL or OMER?

Which has higher earnings and valuation, GRAL or OMER?

Which has more volatility and risk, GRAL or OMER?

Is GRAL or OMER more profitable?

Does the media prefer GRAL or OMER?

Do analysts prefer GRAL or OMER?

Summary

How does Omeros compare to Cogent Biosciences?

Does the media prefer COGT or OMER?

Do analysts rate COGT or OMER?

Is COGT or OMER more profitable?

Do institutionals and insiders hold more shares of COGT or OMER?

Which has more risk and volatility, COGT or OMER?

Which has higher valuation & earnings, COGT or OMER?

Summary

How does Omeros compare to Travere Therapeutics?

Does the media favor OMER or TVTX?

Do institutionals and insiders hold more shares of OMER or TVTX?

Do analysts prefer OMER or TVTX?

Which has higher valuation and earnings, OMER or TVTX?

Is OMER or TVTX more profitable?

Which has more risk & volatility, OMER or TVTX?

Summary

How does Omeros compare to Oruka Therapeutics?

Do analysts prefer OMER or ORKA?

Do insiders & institutionals have more ownership in OMER or ORKA?

Does the media refer more to OMER or ORKA?

Is OMER or ORKA more profitable?

Which has more risk and volatility, OMER or ORKA?

Which has stronger valuation and earnings, OMER or ORKA?

Summary

How does Omeros compare to CRISPR Therapeutics?

Which has more risk & volatility, OMER or CRSP?

Does the media refer more to OMER or CRSP?

Is OMER or CRSP more profitable?

Do institutionals and insiders have more ownership in OMER or CRSP?

Which has better earnings & valuation, OMER or CRSP?

Do analysts prefer OMER or CRSP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools